Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

News in Brief

T-DM1 Extends Survival in HER2+ Breast Cancer

DOI: 10.1158/2159-8290.CD-NB2015-174 Published February 2016
  • Article
  • Info & Metrics
Loading

According to results from the phase III TH3RESA study, the antibody–drug conjugate ado-trastuzumab emtansine (Kadcyla; Roche)—commonly called T-DM1—increases overall survival (OS) in patients with metastatic HER2-positive (HER2+) breast cancer who have already received multiple treatments. The data were presented by Hans Wildiers, MD, PhD, a medical oncologist at the University of Leuven in Belgium, during the 2015 San Antonio Breast Cancer Symposium in Texas, held December 8–12.

T-DM1's 2013 approval was based on the phase III EMILIA study, in which enrolled patients—all previously treated with trastuzumab (Herceptin; Roche) or taxane chemotherapy—had a considerably longer median progression-free survival (PFS) and OS on T-DM1, compared with those who received lapatinib (Tykerb; GlaxoSmithKline) plus capecitabine (Xeloda; Roche).

“The goal of TH3RESA was to investigate T-DM1 in a still more advanced patient population, compared to EMILIA,” Wildiers explained. The study's 602 participants had all been on prior regimens that included a taxane and two or more HER2-directed therapies, including trastuzumab and lapatinib. They were randomized to receive T-DM1 or treatment of physician's choice (TPC)—the latter being “a pragmatic approach that's increasingly used” as a control in clinical trials where there are multiple, equally reasonable courses of action and no consensus standard therapy, Wildiers said. He noted that approximately 80% of patients in the TPC arm were given trastuzumab-containing regimens, and because crossover to the other arm was allowed upon disease progression, at least 50% eventually received T-DM1.

Patients treated with T-DM1 had a median OS of 22.7 months, compared with 15.8 months for those given TPC, Wildiers reported. He called this gain of nearly 7 months “highly significant, because there are several breast cancer therapies that increase PFS but not OS, and these patients urgently need new options.” The OS benefit seen with T-DM1 was virtually unchanged in a follow-up sensitivity analysis, which excluded patients who switched from TPC to T-DM1.

Consistent with other studies, T-DM1's toxicity profile was favorable, with thrombocytopenia being its main side effect. Overall, the frequency of adverse events, notably diarrhea, was higher in the TPC arm. While quality of life was not formally assessed, “it appears to be acceptable in many of the patients I see daily,” Wildiers said.

“I think the clinically meaningful data obtained with TH3RESA, along with that of EMILIA, solidify T-DM1's therapeutic role in advanced, heavily pretreated HER2+ breast cancer,” he added.

“To put these results in perspective, we used to hate diagnosing HER2+ breast cancer in patients, thinking it was one of the more aggressive forms,” said Kent Osborne, MD, director of Baylor College of Medicine's Cancer Center in Houston, TX. “Now, with effective targeted therapies available, it's actually turned out to be a good disease subtype to have.” –Alissa Poh

  • ©2015 American Association for Cancer Research.
Previous
Back to top
Cancer Discovery: 6 (2)
February 2016
Volume 6, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
T-DM1 Extends Survival in HER2+ Breast Cancer
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
T-DM1 Extends Survival in HER2+ Breast Cancer
Cancer Discov February 1 2016 (6) (2) OF4; DOI: 10.1158/2159-8290.CD-NB2015-174

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
T-DM1 Extends Survival in HER2+ Breast Cancer
Cancer Discov February 1 2016 (6) (2) OF4; DOI: 10.1158/2159-8290.CD-NB2015-174
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • By The Numbers: Novel Drugs Approved by the FDA, 2011-2020
  • The National Cancer Act at 50
  • Congress Approves Increase in Cancer Funding
Show more News in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement